Obinutuzumab (GA101) - a different anti-CD20 antibody with great expectations

被引：13
|
作者：
Illidge, Tim M. [1 ]
机构：
[1] Univ Manchester, Sch Canc & Enabling Sci, Manchester Acad Hlth Sci Ctr, Sch Med, Manchester M20 4BX, Lancs, England
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2012年 / 12卷 / 05期
关键词：
CD20; immunotherapy; lymphoid malignancies; mAb; newer agents; CHRONIC LYMPHOCYTIC-LEUKEMIA; MANTLE CELL LYMPHOMA; RITUXIMAB; CD20;
D O I：
10.1517/14712598.2012.668881
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：543 / 545
页数：3
相关论文
共 50 条
  • [1] GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption
    Waseem Bakkour
    Ian H. Coulson
    [J]. Dermatology and Therapy, 2012, 2 (1)
  • [2] GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption
    Bakkour, Waseem
    Coulson, Ian H.
    [J]. DERMATOLOGY AND THERAPY, 2012, 2 (01)
  • [3] A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
    Kensei Tobinai
    Christian Klein
    Naoko Oya
    Günter Fingerle-Rowson
    [J]. Advances in Therapy, 2017, 34 : 324 - 356
  • [4] A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
    Tobinai, Kensei
    Klein, Christian
    Oya, Naoko
    Fingerle-Rowson, Gunter
    [J]. ADVANCES IN THERAPY, 2017, 34 (02) : 324 - 356
  • [5] IN VITRO ANALYSIS OF NOVEL ANTI-CD20 ANTIBODY GA101 AND RITUXIMAB IN MANTLE CELL LYMPHOMA
    Heinrich, D.
    Decheva, K.
    Weinkauf, M.
    Hutter, G.
    Zimmermann, Y.
    Weiglein, T.
    Hiddemann, W.
    Dreyling, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 70 - 70
  • [6] Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
    Dalle, Stephane
    Reslan, Lina
    de Horts, Timothee Besseyre
    Herveau, Stephanie
    Herting, Frank
    Plesa, Adriana
    Friess, Thomas
    Umana, Pablo
    Klein, Christian
    Dumontet, Charles
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (01) : 178 - 185
  • [7] The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model
    Marinov, Anthony D.
    Wang, Haowei
    Bastacky, Sheldon I.
    van Puijenbroek, Erwin
    Schindler, Thomas
    Speziale, Dario
    Perro, Mario
    Klein, Christian
    Nickerson, Kevin M.
    Shlomchik, Mark J.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 (05) : 848 - 857
  • [8] Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
    Salles, Gilles
    Morschhauser, Franck
    Lamy, Thierry
    Milpied, Noel
    Thieblemont, Catherine
    Tilly, Herve
    Bieska, Gabi
    Asikanius, Elina
    Carlile, David
    Birkett, Joe
    Pisa, Pavel
    Cartron, Guillaume
    [J]. BLOOD, 2012, 119 (22) : 5126 - 5132
  • [9] Ga101 is the most effective anti-CD20 mAb in ABC and GCB DLBCL and is antagonized by Ofatumumab via decrease of Ga101 induced apoptosis
    Zoellner, A. -K
    Weber, A.
    Zimmermann, Y.
    Hutter, G.
    Hiddemann, W.
    Dreyling, M.
    [J]. ONKOLOGIE, 2012, 35 : 39 - 40
  • [10] Anti-CD20 Antibody GA101 Shows Higher Cytotoxicity but Is Competitively Displaced by Rituximab in Mantle Cell Lymphoma.
    Heinrich, Daniel A.
    Klein, Christian
    Decheva, Kristina
    Weinkauf, Marc
    Hutter, Grit
    Zimmermann, Yvonne
    Weiglein, Tobias
    Hiddemann, Wolfgang
    Dreyling, Martin H.
    [J]. BLOOD, 2009, 114 (22) : 1059 - 1059
12345